Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Galectin’s NASH Challenges: Paying For Phase III, Carving Market Niche

Nov 22 2019

• By Joseph Haas

Liver Meeting Update, Boston 2019 — Galectin expects to begin its delayed Phase III NASH trial early next year

Related Content

Galectin Offers Subgroup Approach For Struggling NASH Candidate

Dec 06 2017

Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint

May 15 2018

NASH Pipeline Includes Six Candidates That Have Reached Phase III

Oct 01 2019

Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Apr 11 2019

Related Companies

Galectin Therapeutics Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Gilead Sciences, Inc.

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development BioPharmaceutical Liver & Hepatic

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window